Shares of Bristol-Myers Squibb were hit hard in pre-market trading Friday after news that its blockbuster cancer drug failed a key clinical trial. The drug, called Opdivo, is one of a new set of drugs called immunotherapy. The drug targets the programmed cell death 1 (or PD-1) receptor to essentially ... Read More »